Company intelligence / Profile preview
Nanjing Yoko Biomedical Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Nanjing Yoko Biomedical is an innovative Chinese biopharma focused on developing and commercializing new drugs with indigenous intellectual property. The company has achieved approval for antibiotics targeting infectious diseases and is advancing oncology assets into early-phase trials. It also pursues biosimilars through its affiliates/subsidiaries.[5][3][4]
- Therapeutic areas
- OncologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules[1]Monoclonal antibodies[4]Biosimilars[4]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Nanjing Yoko Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Yoko Biomedical Co., Ltd..